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Survivin is a member of the inhibitor of apoptosis protein family. Survivin has splice variants with different biological functions
associated with tumorigenesis. We investigated 134 non-small cell lung cancers (NSCLCs) to study the clinical significance of wild-
type survivin, survivin-2B, and survivin-deltaEx3. Real-time PCR analyses were performed for their gene expressions. The subcellular
localisation of survivin proteins was evaluated by immunohistochemistry. The Ki-67 proliferation index and the apoptotic index were
also evaluated. The survivin-deltaEx3 gene expression was significantly higher in stage II–III than in stage I (P¼0.0174), and significantly
correlated with the nuclear pan-survivin expression (Po0.0001). The Ki-67 index was significantly higher in wild-type survivin-positive
tumours (Po0.0001), survivin-deltaEx3-positive tumours (Po0.0001), and tumours with positive expression of the nuclear pan-
survivin (P¼0.0047). In contrast, the apoptotic index was significantly lower only in wild-type survivin-positive tumours (Po0.0001).
Thus, the wild-type survivin gene expression was associated with apoptotic inhibition and tumour proliferation. Furthermore, the
survivin-deltaEx3 gene expression was strongly associated with tumour proliferation, especially in advanced stage NSCLCs. In contrast,
the survivin-2B gene expression did not correlate with tumour proliferation or tumour apoptosis.
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Non-small cell lung cancer (NSCLC) has become the leading cause of
cancer death in Japan. Clarifying the mechanism of tumour biology
is considered to be important for improving the clinical outcome of
advanced NSCLC patients. Owing to recent developments in
molecular biology, many molecular markers have proven to be
associated with cell cycle regulation, apoptosis, and chemo-radio
resistance. These molecular markers include survivin (Altieri, 2003),
p53 (Vogelstein and Kinzler, 1992), and bcl-2 (Strasser et al, 1997).
Survivin was originally identified as a member of the inhibitor
of apoptosis protein (IAP) family (Ambrosini et al, 1997). To date,
survivin has at least five splice variants; including wild-type
survivin (i.e. survivin itself), survivin-2a, survivin-2B, survivin-
deltaEx3, and survivin-3B (Mahotka et al, 1999; Badran et al, 2004;
Caldas et al, 2005a). Intriguingly, these splice variants are reported
to have different biological functions (Mahotka et al, 2002a).
Among them, recent studies found both wild-type survivin and
survivin-deltaEx3 to demonstrate not only apoptotic inhibition but
also an acceleration of cell proliferation (Honda et al, 2003; Song
and Wu, 2005; Takashima et al, 2005). In contrast, survivin-2B
is considered to attenuate the antiapoptotic function of wild-type
survivin (Caldas et al, 2005b).
The ability to control tumour proliferation and apoptosis may
enable us to develop new strategies for the treatments of NSCLC
patients. Therefore, we performed a study on the gene expressions
of wild-type survivin, survivin-2B, and survivin-deltaEx3 in
relation to the subcellular localisation of survivin protein, the
Ki-67 proliferation index (Gerdes et al, 1984), and the apoptotic
index (Tanaka et al, 2001) to clarify the clinical significance of
these expressions in NSCLCs.
MATERIALS AND METHODS
Clinical characteristics of patients
From June 1999 to December 2002, NSCLC patients, who
underwent surgery at the Second Department of Surgery, Kagawa
University or the Department of Thoracic Surgery, Japanese Red
Cross Society Wakayama Medical Center, were studied. This study
was approved by the institutional review board of Kagawa
University (14-7, a clinical study of biological markers in NSCLCs).
Signed, written informed consent was obtained from all patients
before therapy was initiated. In total, 134 patients up to stage IIIB
were investigated. The patients’ clinical records and histopatho-
logical diagnoses were fully documented.
Real-time PCR for gene expressions
The total cellular RNA was extracted from frozen tissue specimens
by the acid guanidinium thiocyanate procedure. First-strand cDNA
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ssynthesis was performed with 5mg of total RNA using a cDNA
synthesis kit (Pharmacia, Piscataway, NJ, USA). Because real-time
PCR (RT–PCR) is not an appropriate method to discriminate
between wild-type survivin and other splice variants, we carried
out quantitative RT–PCR assays using densitometric analyses
of gel electrophoresis to evaluate the gene expressions of wild-type
survivin, survivin-2B, and survivin-deltaEx3. For the gene expres-
sions of wild-type survivin, survivin-2B, and survivin-deltaEx3,
oligonucleotides were synthesised as PCR primers based on the
published reports (Yamada et al, 2003). The nucleotide sequence
50-CCACCGCATCTCTACATTCA-30 was used as the sense primer
of wild-type survivin and survivin-deltaEx3,5 0-GAGGCTGGCTT
CATCCACTG-30 was used as the sense primer of survivin-2B,
50-TATGTTCCTCTATGGGGTCG-30 as the antisense primer of
wild-type survivin,5 0-GTTCCTCTCTCGTGATCCG-30 as the anti-
sense primer of survivin-2B, and 50-TTTCCTTTGCATGGGGTC-30
as the antisense primer of survivin-deltaEx3. All subsequent assays
were carried out using the parameters that yielded amplification of
wild-type survivin, survivin-2B, survivin-deltaEx3, and b-actin
DNA (the internal control) within a linear range. The reaction
mixture of wild-type survivin or survivin-2B was subjected to 36
PCR amplification cycles of 60s at 941C, 60s at 601C, and 90s at
721C, and that of survivin-deltaEx3 was subjected to 36 PCR
amplification cycles of 60s at 941C, 60s at 551C, and 90s at 721C,
and that of b-actin was subjected to 31 PCR amplification cycles
of 60s at 941C, 60s at 601C, and 90s at 721C. Preparations of a
human adenocarcinoma cell line, A549, were used as positive
controls for gene expressions of wild-type survivin, survivin-2B,
and survivin-deltaEx3. The amplified DNA samples were run on a
1% agarose gel, and the bands were visualised with ethidium
bromide. The densitometric value obtained for a wild-type
survivin, survivin-2B, and survivin-deltaEx3 band in a given
tumour sample was divided by the value of the b-actin, and the
resultant ratio was referred to as the gene expression ratio.
Thereafter, the expression ratio for a given tumour sample was
divided by the expression ratio of A549 to obtain the standardised
gene expression ratio.
Immunohistochemistry
We used a mouse monoclonal antibody against pan-survivin
(sc17779; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA)
diluted at 1:50, and a mouse monoclonal antibody for the Ki-67
antigen (MIB-1; DAKO, Glostrup, Denmark) diluted at 1:40.
Formalin-fixed paraffin-embedded tissue was cut into 4-mm
sections and mounted on poly-L-lysine-coated slides. Sections
were deparaffinised and rehydrated. The slides were then heated in
a microwave for 10min in a 10mmoll
 1 citrate buffer solution at
pH 6.0. After quenching the endogenous peroxidase activity with
0.3% H2O2 (in absolute methanol) for 30min, the sections were
treated for 2h with 5% bovine serum albumin to block nonspecific
staining. Duplicated sections were incubated overnight with
primary antibodies, respectively. Slides were then incubated for
1h with biotinylated secondary antibodies (Vector Laboratories
Inc., Burlingame, CA, USA). The sections were incubated with the
avidin–biotin–peroxidase complex (Vector) for 1h, and antibody
binding was visualised with 3,30-diaminobenzidine tetrahydro-
chloride. Finally, the sections were lightly counterstained with
Mayer’s haematoxylin.
All immunostained sections were independently evaluated by
two authors (JN and MU), without knowledge of the patients’
characteristics. At least 200 tumour cells were scored per  40
field. Regarding pan-survivin expression, the nuclear staining and
the cytoplasmic staining in each section were evaluated, respec-
tively, in a semiquantitative manner that reflected both the
intensity and percentage of cells staining at each intensity. The
intensity was classified as 0 (no staining), þ1 (weak staining), þ2
(distinct staining), or þ3 (very strong staining). A value
designated as the ‘HSCORE’ thus was obtained for each slide by
using the following algorithm: HSCORE¼S (I PC), where I and
PC represent the intensity and the percentage of cells that stain at
each intensity, respectively. The percentage of carcinoma cells with
positive staining for Ki-67 antigen was scored as the Ki-67
proliferation index.
Detection of apoptosis
The presence of apoptotic cells was detected with the TUNEL
method using the In Situ Apoptosis Detection Kit (Takara
Biomedicals, Otsu, Japan). After sections were deparaffinised and
rehydrated, the slides were treated for 15min with 20mgml
 1
Proteinase K. After quenching the endogenous peroxidase activity
with 3% H2O2 for 5min, the sections were then incubated for
90min at 371C with the TUNEL reaction mixture, including
terminal deoxynucleotidyl transferase (TdT). Next, the sections
were incubated for 30min at 371C with anti-FITC horseradish
peroxidase conjugate. Staining was developed using 3,30-diamino-
benzidine tetrahydrochloride for 15min. Finally, the sections were
lightly counterstained with Mayer’s haematoxylin. Sections
incubated with the TUNEL reaction mixture without TdT were used
as negative control slides. Apoptotic cells were determined based
on observations of TUNEL-staining sections and serial HE-staining
sections. Cells staining positive for TUNEL, if they represented the
histologic features of necrosis in HE-staining sections, were not
considered to be apoptotic cells. In each case, a total of 10000
tumour cells were evaluated at high magnification by two authors
(JN and MU) independently, without knowledge of the patients’
characteristics. The apoptotic index was defined as the number
of apoptotic cells per 1000 tumour cells.
Statistical analysis
The ratio of the Ki-67 proliferation index divided by the apoptotic
index was referred to as the growth index for each sample (Tsoli
et al, 2002). The statistical significances of wild-type survivin,
survivin-2B, and survivin-deltaEx3 gene expression in relation to
several clinical and pathological parameters were assessed by t-test
or an analysis of variance with Bonferroni/Dunn test. Because the
wild-type survivin expression cutoff line of 1.0 demonstrated the
most significance in relation to the Ki-67 proliferation index and
the apoptotic index, the sample was classified as a wild-type
survivin-positive tumour when the standardised wild-type survivin
gene expression was 41.0. Because the survivin-deltaEx3 expres-
sion cutoff line of 0.5 demonstrated the most significance
in relation to the Ki-67 proliferation index, the sample was classified
as a survivin-deltaEx3-positive tumour when the standardised
survivin-deltaEx3 gene expression was 40.5. The sample was
classified as a survivin-2B-positive tumour when the standardised
survivin-2B expression was 41.0 (a median value of survivin-2B
gene expression). Samples were considered to have a positive
expression of nuclear pan-survivin if the HSCORE of the nuclear
staining of pan-survivin was more than 10, a positive expression
of cytoplasmic pan-survivin if the HSCORE of the cytoplasmic
staining of pan-survivin was more than 50. All P-values were
based on two-tailed statistical analysis and a P-value of o0.05 was
considered to indicate statistical significance.
RESULTS
Wild-type survivin gene expression in NSCLCs
We studied the wild-type survivin gene expression in eight
noncancerous samples to evaluate its expression in normal lung
tissue. The standardised wild-type survivin gene expression ratio
was low in normal lung tissue specimens (mean 0.363±0.135). In
contrast, the standardised survivin gene expression ratio varied
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1.531±0.795, Figure 1A). The standardised wild-type survivin
gene expression ratio was significantly higher in tumour tissue
specimens than in normal lung tissue specimens (Po0.0001,
Figure 2A). Seventy-two carcinomas (53.7%) were wild-type
survivin-positive tumours. Regarding tumour histology, the wild-
type survivin gene expression was significantly higher in squamous
cell carcinomas than in adenocarcinomas (1.690±0.892
vs 1.362±0.664, P¼0.0181, Table 1). In addition, the wild-type
survivin gene expression was significantly higher in moderately
or poorly differentiated tumours than in well-differentiated
tumours (1.614±0.807 vs 1.288±0.712, P¼0.0383).
Survivin-2B gene expression in NSCLCs
The standardised survivin-2B gene expression ratio was low in
eight normal lung tissue specimens (mean 0.496±0.246). In
contrast, the standardised survivin-2B gene expression ratio also
varied greatly among the tumour tissue specimens (mean
1.233±0.830, Figure 1B). The standardised survivin-2B gene
expression ratio was significantly higher in tumour tissues than
in normal lung tissues (P¼0.0138, Figure 2B). However, no
difference was observed in the survivin-2B gene expression
regarding tumour histology, tumour differentiation, or any other
clinicopathological parameter (Table 1).
Survivin-deltaEx3 gene expression in NSCLCs
The standardised survivin-deltaEx3 gene expression ratio was low
in eight normal lung tissue specimens (mean 0.296±0.098). In
contrast, the standardised survivin-deltaEx3 gene expression ratio
varied greatly among the tumour tissue specimens (mean
0.971±0.610, Figure 1C). The standardised survivin-deltaEx3 gene
expression ratio was significantly higher in tumour tissues than in
normal lung tissues (P¼0.0022, Figure 2C). One hundred and one
carcinomas (75.4%) were survivin-deltaEx3-positive tumours.
Regarding tumour histology, the survivin-deltaEx3 gene expres-
sion was also significantly higher in squamous cell carcinomas
than in adenocarcinomas (1.075±0.616 vs 0.854±0.587,
P¼0.0377, Table 1). Regarding tumour differentiation, the
survivin-deltaEx3 gene expression was significantly higher in
moderately or poorly differentiated tumours than in well-
differentiated tumours (1.049±0.619 vs 0.743±0.526, P¼0.0110).
Regarding the clinicopathological characteristics, the survivin-
deltaEx3 gene expression was significantly higher in stage II–III
NSCLCs than in stage I NSCLCs (1.084±0.661 vs 0.833±0.512,
P¼0.0174).
Subcellular localisation of the survivin protein expression
in relation to wild-type survivin, survivin-2B, and survivin-
deltaEx3 gene expressions. Immunostaining using the antibody
against pan-survivin showed various patterns of cytoplasmic
staining and nuclear staining (Figure 3A and C). Regarding the
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Figure 2 Standardised gene expression ratio in normal lung tissues and tumour tissues. (A) Wild-type survivin,( B) survivin-2B, and (C) survivin-deltaEx3.
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Figure 1 Agarose gel electrophoresis of RT–PCR-amplified (A) wild-
type survivin cDNA, (B) survivin-2B cDNA, (C) survivin-deltaEx3 cDNA,
and (D) b-actin cDNA (internal PCR control). Lane 1, size marker; lane 2,
A549 (positive control); lane 3, normal lung tissue; lanes 4 and 5, low
expression of both wild-type survivin and survivin-deltaEx3; lanes 6 and 7,
high expression of both wild-type survivin and survivin-deltaEx3.RT–
PCR¼real-time PCR.
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sTable 1 Gene expression of wild-type survivin, survivin-2B, and survivin-deltaEx3 in 134 NSCLCs according to clinical characteristics
Wild-type survivin Survivin-2B Survivin-deltaEx3
Variables n
Standardised
gene expression
ratio P-value
Standardised
gene expression
ratio P-value
Standardised
gene expression
ratio P-value
Tumour status
T1 46 1.407±0.786 0.3145 1.472±1.094 0.6335 0.922±0.614 0.3219
T2 48 1.475±0.698 0.985±0.515 0.884±0.526
T3 22 1.817±0.885 1.345±0.747 1.189±0.720
T4 18 1.646±0.905 1.144±0.681 1.063±0.638
Nodal status
N0 86 1.459±0.835 0.1613 1.265±0.748 0.5628 0.902±0.564 0.0781
N1, N2, N3 48 1.660±0.707 1.175±0.914 1.096±0.673
Pathological stage
Stage I 60 1.385±0.819 0.0558 1.281±0.796 0.5626 0.833±0.512 0.0174
Stage II, III 74 1.649±0.759 1.194±0.860 1.084±0.661
Differentiation
Well 34 1.288±0.712 0.0383 1.318±0.832 0.4964 0.743±0.526 0.0110
Moderately or poorly 100 1.614±0.807 1.203±0.832 1.049±0.619
Histology
Adenocarcinoma 66 1.362±0.664 0.0181
a 1.192±0.736 0.5191
a 0.854±0.587 0.0377
a
Squamous cell carcinoma 65 1.690±0.892 1.285±0.923 1.075±0.616
Large cell carcinoma 3 1.780±0.570 0.850±0.507 1.321±0.620
Total 134 1.531±0.795 1.233±0.830 0.971±0.610
Abbreviation: NSCLCs¼non-small cell lung cancers.
aSquamous cell carcinoma vs adenocarcinoma.
AB
CD
E
Figure 3 Immunostaining of lung cancers. Squamous cell carcinoma with (A) strongly positive expression of both nuclear and cytoplasmic pan-survivin,
(B) high Ki-67 index. Adenocarcinoma with only (C) positive expression of cytoplasmic pan-survivin, (D) low Ki-67 index. (E) Adenocarcinoma with high
apoptotic index.
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expression of cytoplasmic pan-survivin. However, the HSCORE
of the cytoplasmic pan-survivin did not correlate with the gene
expression of wild-type survivin, survivin-2B, or survivin-deltaEx3.
On the other hand, regarding the nuclear staining, 88
carcinomas (65.7%) had a positive expression of nuclear pan-
survivin. Furthermore, the standardised survivin-deltaEx3 gene
expression significantly correlated with the HSCORE for the
nuclear staining of pan-survivin (r¼0.642, Po0.0001). However,
the HSCORE of the nuclear pan-survivin did not correlate with the
gene expression of wild-type survivin or survivin-2B.
Ki-67 proliferation index in NSCLCs
The Ki-67 proliferation index ranged from 2.0 to 95.0 (mean
47.6±27.3, Figure 3B and D). Regarding the gene expressions of
splice variants of survivin, the Ki-67 proliferation index was
significantly higher in the wild-type survivin-positive tumours
than in the wild-type survivin-negative tumours (57.4±22.0 vs
36.2±28.5, Po0.0001, Figure 4A, Table 2). However, there was no
difference in the Ki-67 proliferation index according to the
survivin-2B gene expression (Figure 4B). In contrast, the Ki-67
proliferation index was also significantly higher in the survivin-
deltaEx3-positive tumours than in the survivin-deltaEx3-negative
tumours (53.4±25.5 vs 29.8±25.0, Po0.0001, Figure 4C). Regard-
ing the subcellular localisation of pan-survivin protein, the Ki-67
proliferation index was significantly higher in tumours with
a positive expression of nuclear pan-survivin than in tumours
with a negative expression of nuclear pan-survivin (52.4±26.5 vs
38.5±26.6, P¼0.0047, Figure 4D). In contrast, there was no
difference in the Ki-67 proliferation index according to the
cytoplasmic pan-survivin expression (Figure 4E).
Apoptotic index in NSCLCs
The apoptotic index ranged from 10.0 to 40.0 (mean 20.7±7.4,
Figure 3E). Regarding the gene expressions of splice variants of
survivin, the apoptotic index was significantly lower in the wild-
type survivin-positive tumours than in the wild-type survivin-
negative tumours (18.1±5.6 vs 23.1±7.2, Po0.0001, Figure 5A).
On the other hand, there was no difference in the apoptotic index
according to the survivin-2B expression or survivin-deltaEx3
expression (Figure 5B and C). Regarding the pan-survivin protein
expression, neither the nuclear pan-survivin expression nor
the cytoplasmic pan-survivin expression was associated with the
apoptotic index (Figure 5D and E).
Growth index in NSCLCs
The growth index ranged from 0.05 to 9.00 (mean 2.62±1.79). The
growth index was significantly higher in the wild-type survivin-
positive tumours than in the wild-type survivin-negative tumours
(3.47±1.68 vs 1.66±1.37, Po0.0001, Figure 6A). However, there
was no difference in the growth index according to the survivin-2B
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Figure 4 Ki-67 proliferation index in relation to wild-type survivin gene expression (A), survivin-2B gene expression (B), survivin-deltaEx3 gene expression
(C), nuclear pan-survivin expression (D), and cytoplasmic pan-survivin expression (E).
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sgene expression (Figure 6B). In contrast, the growth index was also
significantly higher in the survivin-deltaEx3-positive tumours
than in the survivin-deltaEx3-negative tumours (3.01±1.76
vs 1.48±1.33, Po0.0001, Figure 6C). Regarding the subcellular
localisation of pan-survivin protein, the growth index was
significantly higher in tumours with a positive expression of
Table 2 Biological behaviours in relation to gene expressions of survivin variants and survivin protein expressions
n Ki-67 proliferation index Apoptotic index Growth index
Wild-type survivin
Positive 72 57.4±22.0 Po0.0001 18.1±5.6 Po0.0001 3.47±1.68 Po0.0001
Negative 62 36.2±28.5 23.1±7.2 1.66±1.37
Survivin-2B
Positive 72 50.0±26.4 P¼0.1776 19.8±6.9 P¼0.3399 2.86±1.76 P¼0.0583
Negative 62 43.4±28.2 21.0±6.5 2.28±1.64
Survivin-deltaEx3
Positive 101 53.4±25.5 Po0.0001 20.0±6.7 P¼0.1872 3.01±1.76 Po0.0001
Negative 33 29.8±25.0 21.8±7.1 1.48±1.33
Nuclear survivin
Positive 88 52.4±26.5 P¼0.0047 19.9±7.0 P¼0.2662 3.02±1.88 P¼0.0004
Negative 46 38.5±26.6 21.3±6.5 1.90±1.33
Cytoplasmic survivin
Positive 98 48.3±26.9 P¼0.6075 20.1±6.7 P¼0.4464 2.70±1.81 P¼0.4805
Negative 36 45.6±28.7 21.1±7.2 2.45±1.74
Negative
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Figure 5 Apoptotic index in relation to wild-type survivin gene expression (A), survivin-2B gene expression (B), survivin-deltaEx3 gene expression (C),
nuclear pan-survivin expression (D), and cytoplasmic pan-survivin expression (E).
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of nuclear pan-survivin (3.02±1.88 vs 1.90±1.33, P¼0.0004,
Figure 6D). In contrast, there was no difference in the growth
index according to the cytoplasmic pan-survivin expression
(Figure 6E).
DISCUSSION
Survivin is reported to be expressed in most human malignancies
(Kawasaki et al, 1998; Monzo et al, 1999; Sui et al, 2002), while its
expression is absent in normal differentiated tissues (Salvesen and
Duckett, 2002). Although survivin was initially identified as a
member of the IAP family (Ambrosini et al, 1997), recent studies
have demonstrated that survivin not only inhibits the caspase-
dependent apoptotic pathway, but also accelerates cell prolifera-
tion (Honda et al, 2003).
Survivin is known to have at least five spliced variants. These
splice variants have different biological functions (Mahotka et al,
2002a). Among them, recent experimental studies demonstrated
that survivin-deltaEx3 also inhibits apoptosis and induces cell
proliferation, similar to wild-type survivin (Song and Wu, 2005;
Takashima et al, 2005). In contrast, survivin-2a and survivin-2B
are considered to attenuate the antiapoptotic function of wild-type
survivin (Caldas et al, 2005b).
As a result, these splice variants are variably involved in the
biological functions associated with carcinogenesis, including cell
proliferation, apoptosis, and chemo-radio resistance. Previous
clinical studies have reported the survivin expression to be
associated with tumour cell proliferation, apoptotic inhibition,
and a poor prognosis in various human cancers, including NSCLCs
(Martinez et al, 2004; Shinohara et al, 2005). However, only a few
clinical reports studied these splice variants of survivin in human
cancers (Mahotka et al, 2002a; Meng et al, 2004; Ling et al, 2005;
Taubert et al, 2005). Therefore, to clarify the clinical significance of
these splice variants of survivin in NSCLCs, we performed the
present study on the gene expressions of wild-type survivin,
survivin-2B, and survivin-deltaEx3 in relation to the subcellular
localisation of survivin proteins, tumour cell proliferation, and
apoptosis.
In the present study, regarding the relationship of the
expression of these splice variants of survivin, the survivin-
deltaEx3 gene expression significantly correlated with the
wild-type survivin gene expression (r¼0.646, Po0.001). However,
the correlation between the survivin-2B gene expression and the
wild-type survivin gene expression was low (r¼0.254). Regarding
the biological significance of these splice variants of survivin, the
present study also demonstrated the wild-type survivin gene
expression to be associated with both tumour cell proliferation and
apoptotic inhibition. In contrast, the survivin-deltaEx3 gene
expression correlated with the nuclear pan-survivin expression.
Furthermore, both the survivin-deltaEx3 gene expression and the
nuclear pan-survivin expression were found to be associated with
tumour cell proliferation, but not with apoptotic inhibition.
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sHowever, the survivin-2B gene expression did not correlate with
tumour cell proliferation or apoptotic inhibition. In total, the
growth index was associated with both the wild-type survivin
expression and the survivin-deltaEx3 expression. As a result, the
present study revealed wild-type survivin to be associated with
both tumour cell proliferation and apoptotic inhibition, while
survivin-deltaEx3 was strongly associated with tumour cell
proliferation.
In fact, previous clinical studies also revealed the survivin-
deltaEx3 expression to be associated with a high proliferation rate
(Takashima et al, 2005). Recent studies have revealed that the
survivin-deltaEx3 overexpression is a significant poor prognostic
factor in cancer patients, including NSCLCs (Ling et al, 2005;
Taubert et al, 2005). Furthermore, the present study found the
survivin-deltaEx3 gene expression to be significantly higher in
advanced-stage NSCLCs. Therefore, the survivin-deltaEx3 gene
overexpression could produce more aggressive tumours with a
high proliferation rate in advanced-stage NSCLCs. Because the
biomarkers associated with tumour proliferation are significant
factors in advanced-stage NSCLCs (Huang et al, 2005), the level
of the survivin-deltaEx3 gene expression could thus affect the
clinical impact of NSCLCs, especially in the advanced stages. A
recent study on soft tissue sarcoma also reported the over-
expression of survivin-deltaEx3 gene to correlate with an advanced
clinical stage and a poor prognosis (Taubert et al, 2005).
On the other hand, previous immunohistochemical studies
revealed the nuclear expression of survivin proteins also to be
associated with tumour cell proliferation and a poor prognosis in
cancer patients, as was also shown in the present study, while the
cytoplasmic expression of survivin proteins was not (Martinez
et al, 2004; Huang et al, 2005; Ling et al, 2005; Shinohara et al,
2005; Taubert et al, 2005). These studies were performed using
antibodies against pan-survivin, which cannot distinguish wild-
type survivin from other spliced variants. In general, wild-type
survivin is considered to be located both in the cytoplasm for
apoptotic inhibition, and in the nuclei for cell proliferation. In
contrast, survivin-deltaEx3 is probably located in the nucleus
because of its nuclear localisation signal (Mahotka et al, 2002b;
Song and Wu, 2005). The present study also demonstrated
the survivin-deltaEx3 gene expression to correlate with the nuclear
pan-survivin expression. As a result of the above findings, the
nuclear expression of pan-survivin could be the representation
of both wild-type survivin and survivin-deltaEx3, both of which are
associated with tumour proliferation. In contrast, the cytoplasmic
expression of pan-survivin might indicate the presence of wild-
type survivin and survivin-2B (Mahotka et al, 2002b). In fact, the
present study revealed that the cytoplasmic pan-survivin expres-
sion was not associated with the apoptotic index. This result might
be partly because cytoplasmic survivin-2B can inhibit the
antiapoptotic function of wild-type survivin. We performed
additional immunohistochemistry to clearly identify the sub-
cellular localisation of survivin-deltaEx3 using a commercially
available specific antibody against survivin-deltaEx3; however,
we were not successful (data not shown).
As a result, the present study demonstrated the wild-type
survivin gene expression to be associated with not only apoptotic
inhibition but also tumour proliferation. In contrast, the survivin
deltaEx3 gene expression significantly correlated with the nuclear
expression of pan-survivin and the Ki-67 proliferation index.
However, the survivin 2B gene expression did not correlate with
tumour proliferation or tumour apoptosis. Considering these
results, the combined evaluations of wild-type survivin and
survivin-deltaEx3 gene expression may thus be a useful strategy
for evaluating NSCLCs. The RNA inhibition of survivin can induce
apoptosis in human tumour cell lines (Ambrosini et al, 1998; Olie
et al, 2000). Therefore, the RNA inhibition designed against
common regions of both the wild-type survivin and the survivin-
deltaEx3 could be a more effective strategy for NSCLCs not only to
improve the efficacy of chemo-radio therapy but also to suppress
tumour cell proliferation (Li et al, 1998; Lu et al, 2004).
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